Here's Why 2022 Could Be a Huge Year for GlaxoSmithKline
Since the first report of AIDS in 1981, the scientific community has been working tirelessly to develop therapies for AIDS, as well as preventative treatments for the initial stages, HIV.
HIV specialist ViiV Healthcare is majority-owned by GlaxoSmithKline (NYSE: GSK) with Pfizer (NYSE: PFE) and Shionogi as fellow shareholders. ViiV Healthcare announced last month that the U.S. Food and Drug Administration (FDA) accepted and granted priority review for its injectable, long-acting pre-exposure prophylaxis (PrEP) drug known as cabotegravir. With the FDA targeting a decision on the drug by Jan. 24, 2022, what could this revolutionary prophylactic HIV treatment mean for GlaxoSmithKline? Let's find out by examining the appeal and the efficacy of cabotegravir, as well as the sales potential of the drug.
Image source: Getty Images.
Source Fool.com
